Cefiderocol
Cefiderocol is a pharmaceutical drug with 18 clinical trials. Currently 3 active trials ongoing. Historical success rate of 92.9%.
Success Metrics
Based on 13 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
5
Mid Stage
6
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
92.9%
13 of 14 finished
7.1%
1 ended early
3
trials recruiting
18
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants
A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants
Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii
Clinical Trials (18)
Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants
A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants
Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii
Optimising TREATment for Severe Gram-Negative Bacterial Infections
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants
Cefiderocol Plasma Concentrations in Patients Receiving Renal Replacement Therapy
Cefiderocol PK in Patients on ECMO
Cefiderocol Pharmacokinetics in Adult Patients With Cystic Fibrosis
RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI
A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy Participants
Use of Cefiderocol in the Management of Gram-Negative Infections
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens
Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia
Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections
A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections
All 18 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 18